PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
- Successfully completed international MDMA shipment to Yale University for clinical trials
- Expanding research applications for MDMA into new therapeutic areas (Borderline Personality Disorder and Narcissistic Personality)
- Strategic partnership with MAPS through public sharing of Investigator's Brochure, potentially increasing LaNeo MDMA adoption
- Management alignment with shareholders through issuance of stock options
- Facing significant cross-border friction for US exports
- Stock options issued at $0.105 represent potential future dilution
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to Yale University.
“We’re very pleased to have delivered this shipment to Yale, achieved despite significant cross-border friction. We are continuing to obtain permits to export to US, with more to come,” said Nick Kadysh, Founding CEO, PharmAla Biotech. “Following our news from March of our successful delivery of LaNeo™ MDMA for a trial at the University of Washington, this is the second new pilot study with a novel indication for MDMA enabled by PharmAla: first Narcistic Personality, and now Borderline Personality Disorder. Ultimately, this work is not only important for advancing science, but for potentially opening new markets for PharmAla’s products.”
The shipment will be used for an open-label trial which will investigate the effects of a dose of MDMA on social cognition in adults with Borderline Personality Disorder.
“We are grateful to the PharmAla Team for their hard work in making this delivery happen,” said Dr. Sarah Fineberg, Principal Investigator for the trial. “We’re thrilled to begin our trial, and look forward to future developments.”
Authorization to MAPS to post PharmAla Investigator’s Brochure
PharmAla has granted the Multidisciplinary Association for Psychedelic Studies (MAPS) authorization to post the PharmAla LaNeo MDMA Investigator’s Brochure (IB) publicly on the MAPS website. Access to the PharmAla Investigator’s Brochure has thus far been solely reserved for researchers working with PharmAla Biotech.
“Pharmala's willingness to post its Investigators Brochure summarizing the scientific research on the risks and benefits of MDMA on the MAPS website is a major contribution to researchers all over the world considering whether to study MDMA,” said Rick Doblin, Founder of MAPS. “Pharmala being open to providing researchers both GMP MDMA, and knowledge about MDMA research in its Investigator's Brochure, is a model for the industry.”
PharmAla hopes that greater access to the PharmAla IB will encourage continued adoption of PharmAla’s LaNeo™ MDMA for clinical trial and patient use. The PharmAla IB remains the sole copyrighted work of PharmAla Biotech, all rights reserved.
Issuance of Options
PharmAla has issued options to the following Board Members and Officers. The options are issued subject to a vesting period, such that every 3 months
| Name of Optionee | Position | Number of Options | |
| Jodi Butts | Director | 100,000 | |
| Kevin Roy | Director | 100,000 | |
| Fraser Macdonald | Director | 100,000 | |
| Perry Tsergas | Director | 100,000 | |
| Harriet De Wit | Director | 100,000 | |
| Abdelmalik Slassi | Director | 100,000 | |
| Will Avery | Chief Financial Officer | 100,000 | |
| Shane Morris | Chief Operating Officer | 100,000 | |
| Ali Taghva | Chief Commercial Officer | 100,000 | |
| Harpreet Kuar | Employee | 100,000 | |
| Nicholas Kadysh | Chief Executive Officer | 500,000 | |
| Total | 1,500,000 | ||
PharmAla to appear at the Canadian Security Exchange’s Summit on Responsible Investment
PharmAla’s CEO, Nicholas Kadysh, will appear at the CSE’s Summit on Responsible Investing in Kelowna, BC, this Thursday, June 5, 2025.
For more information, please visit www.PharmAla.ca, where you can sign up to receive regular news updates.
About PharmAla
PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
For more information, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmAla’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by PharmAla at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and PharmAla is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in PharmAla’s management’s discussion and analysis which is available on PharmAla’s profile at www.sedar.com.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
FAQ
What is the purpose of PharmAla's (MDXXF) MDMA shipment to Yale University?
How many stock options did PharmAla issue and at what price?
What is the significance of PharmAla sharing its Investigator's Brochure with MAPS?
What are the new therapeutic applications being explored for PharmAla's LaNeo MDMA?
How many options did PharmAla's CEO Nicholas Kadysh receive?
